SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure amid its boards investigation into CEO Jensen Huangs admitted affair with a businesswoman alleged to have ties to Chinese intelligence, raising speculation about national-security scrutiny and Huangs job security. Traders are split between fearing leadership disruption or further damaging disclosures and viewing the controversy as separate from Nvidias business and a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

The Q3 earnings report is the main focus as Hims shares sell off into the release; traders are divided between hopes for a beat and stronger guidance and concerns about margin pressure, including from the shift toward branded weight-loss drugs through the Eli Lilly partnership. Claims that results leaked are speculation, not confirmed.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.11892236 USD and is down -3.62 over the last 24 hours. It is currently trading on 1894 active market(s) with $1,884,610,999.15 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp slide toward the $1 area amid a broader crypto selloff is driving the discussion, with traders debating whether support will hold or the decline will deepen. Some blame market-wide weakness and regulatory uncertainty, while others criticize XRPs utility and Ripples token economics; a smaller group sees the dip as an accumulation opportunity.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desks sharp rally ahead of its Q3 earnings report has traders speculating about short covering or an earnings surprise, though claims of a leak are unverified. The community is split between hopes that low expectations and improving ad-tech results will support a rebound and concern that weak growth or guidance could reverse the move.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs rally is being tied to an Oppenheimer upgrade and Googles use of AMD EPYC processors in its new AI infrastructure, reinforcing the companys data-center growth story. Traders also speculate that Nvidias CEO controversy is prompting a rotation into AMD, though some question the valuation and warn the sharp move could fade.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Agility Robotics Inc.

Agility Robotics Inc. - Ordinary Shares - Class A

A sharp post-merger selloff is driving discussion, with traders attributing the pressure to de-SPAC selling and skepticism about Agilitys early-stage finances. Some remain bullish on its humanoid-robotics prospects and cited multiyear Digit orders, while others are waiting for the financial report before judging the business.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly results and higher full-year revenue outlook, driven by continued BRIUMVI growth, dominate discussion. Despite the positive update, shares pulled back, prompting buy-the-dip responses and frustration over a perceived sell-the-news move; traders are also watching the subcutaneous BRIUMVI Phase 3 readout, while buyout speculation remains unconfirmed.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two is drawing attention ahead of its fiscal report and GTA VIs scheduled launch, with traders watching for bookings guidance and preorder commentary while debating whether blockbuster demand and future online monetization are already priced in. Bulls see the release as a major growth catalyst, while skeptics warn that expectations are high and the stock could sell off on earnings or become a sell-the-news trade.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Traders are focused on the FDAs November 22 decision on Capricors deramiocel for Duchenne muscular dystrophy, particularly the amended applications upper-limb function data. Bulls cite the HOPE-3 results and physician support, while skeptics point to past FDA concerns and the binary approval risk; short-squeeze speculation is also prominent.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is caught in volatile, election-driven market swings, with traders linking the broader selloff to uncertainty over AI and data-center policy and debating whether it signals further downside or a buying opportunity. The community is split between bearish technical and options positioning and hopes that small caps will rebound or benefit from a rotation out of large-cap tech.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events

IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations EventsPR NewswireSOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- IDEAYA...

IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates

IDEAYA Biosciences (IDYA) delivered earnings and revenue surprises of +3.18% and +14.69%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business UpdatePR NewswireSOUTH SAN FRANCISCO, Calif., Nov. 3, 2026 Data presented at ESMO 2026 collectively...

Vertex Pharmaceuticals (VRTX) Misses Q3 Earnings Estimates

Vertex (VRTX) delivered earnings and revenue surprises of -3.25% and +1.11%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireSOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences...

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates...

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at...

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and DevelopmentPR NewswireSOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 SOUTH SAN FRANCISCO, Calif., Sept. 28...

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Nasdaq, S&P 500 Futures Slip As Hormuz Blockade Escalates Tensions: Why BATL, INTC, PLTR, IDYA Are On Traders' Radar Today

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Talks between the U.S. and Iran in Pakistan ended without a deal, followed by President Donald Trump ordering a naval blockade targeting shipping linked to Iranian ports.</li><li>Crude surges above $100, fueling a potential rotation into energy and defense stocks.</li><li>Big bank earnings this week, alongside key economic data, are adding to a volatile setup.&nbsp;</li></ul>U.S. stock futures were under pressure early Monday amid escalating geopolitical tensions over the weekend. U.S.-Iran talks in Pakistan ended without a deal, followed by President Donald Trump ordering a naval blockade of the Strait of Hormuz, effective at 10 AM ET on Monday, sending crude prices surging back above $100. Reports suggest the U.S. could consider renewed military strikes, while Iran continues to push demands around nuclear policy and control over key waterways.As of 4:00 a.m. ET on Monday, Dow futures fell 0.5%, S&amp;P 500 futures declined 0.6%, Nasdaq futures were down 0.7%, and Russell 2000 futures slumped 1%.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has been languishing at ‘extremely bearish’ amid high trading volume.&nbsp;Trending Stocks To WatchA massive week for earnings kicks off with&nbsp;Goldman Sachs (GS) reporting this morning.&nbsp;With crude oil prices rising again, watch out for oil-related stocks (USO, BATL, EONR, XOM, CVX, TPET) in trade today, and a potential rotation into&nbsp;defense stocks as well (AVAV, LMT).Software stocks such as&nbsp;Palantir (PLTR) and ServiceNow (NOW) remain on the retail radar amid fears that AI agents will cannibalize the traditional software model. Meanwhile,&nbsp;Cathie Wood’s ARK Investment Management bought about 85,500 PLTR shares on Friday.Intel (INTC)&nbsp;was among the most overbought stocks last week. However, its 14-day Relative Strength Index (RSI) above 70 suggests a pullback may be looming.&nbsp;Jefferies has raised its price target to $60 from $45 and maintains a Hold rating on the shares.Sandisk (SNDK):&nbsp;Shares rose nearly 2% in early pre-market trade after being tapped to replace Atlassian (TEAM) in the NASDAQ 100, effective April 20.Amid biotech stocks,&nbsp;Ideaya Biosciences (IDYA) is surging nearly 20% in early pre-market trade ahead of critical Phase 2/3 cancer drug data due at 8:00 AM ET today.&nbsp;Regeneron (REGN) and Sanofi earned EU approval for&nbsp;Dupixent&nbsp;to treat chronic spontaneous urticaria in children (ages 2-11).&nbsp;Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Strategy (MSTR), Lightwave Logic (LWLG), Clene (CLNN), and Avis Budget Group (CAR).&nbsp;Other Catalysts To WatchOn the economic front, traders will be watching for the release of March existing home sales data.&nbsp;On earnings radar, watch out for quarterly reports from Goldman Sachs (GS), Iveda Solutions Inc (IVDA), and Fastenal (FAST) before the bell. Meanwhile, ZENA, XTI Aerospace Inc. (XTIA), Ozop Energy Solutions (OZSC), and Dark Pulse Inc (DPLS), among others, report after market close today.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Data from Stocktwits shows that retail sentiment remains deeply bearish on SPY and QQQ.

Battalion Oil Corp - Ordinary Shares (New)

Intel Corp

Palantir Technologies Inc

Sandisk Corp

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$1.18	--	--	N/A
Q3 '26	-$1.18	-$1.22	-3.43%	MISSED
Q2 '26	-$1.06	-$1.22	-15.47%	MISSED
Q1 '26	-$0.99	-$1.11	-12.26%	MISSED
Q4 '25	-$0.95	-$0.94	1.23%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

IDYA Earnings

Latest Earnings Results: Q3 '26

Historical Earnings